» Articles » PMID: 31374959

Mucosal Vaccination Via the Respiratory Tract

Overview
Journal Pharmaceutics
Publisher MDPI
Date 2019 Aug 4
PMID 31374959
Citations 46
Authors
Affiliations
Soon will be listed here.
Abstract

Vaccine delivery via mucosal surfaces is an interesting alternative to parenteral vaccine administration, as it avoids the use of a needle and syringe. Mucosal vaccine administration also targets the mucosal immune system, which is the largest lymphoid tissue in the human body. The mucosal immune response involves systemic, antigen-specific humoral and cellular immune response in addition to a local response which is characterised by a predominantly cytotoxic T cell response in combination with secreted IgA. This antibody facilitates pathogen recognition and deletion prior to entrance into the body. Hence, administration via the respiratory mucosa can be favoured for all pathogens which use the respiratory tract as entry to the body, such as influenza and for all diseases directly affecting the respiratory tract such as pneumonia. Additionally, the different mucosal tissues of the human body are interconnected via the so-called "common mucosal immune system", which allows induction of an antigen-specific immune response in distant mucosal sites. Finally, mucosal administration is also interesting in the area of therapeutic vaccination, in which a predominant cellular immune response is required, as this can efficiently be induced by this route of delivery. The review gives an introduction to respiratory vaccination, formulation approaches and application strategies.

Citing Articles

Immunological Insights and Therapeutic Advances in COPD: Exploring Oral Bacterial Vaccines for Immune Modulation and Clinical Improvement.

Lewicki S, Balan B, Stelmasiak M, Radomska-Lesniewska D, Szymanski L, Rios-Turek N Vaccines (Basel). 2025; 13(2).

PMID: 40006655 PMC: 11861055. DOI: 10.3390/vaccines13020107.


Cyclic di AMP phosphodiesterase nanovaccine elicits protective immunity against Burkholderia cenocepacia infection in mice.

Gawad W, Nagy Y, Samir T, Mansour A, Helmy O NPJ Vaccines. 2025; 10(1):22.

PMID: 39893156 PMC: 11787396. DOI: 10.1038/s41541-025-01074-4.


Novel vaccine strategies to induce respiratory mucosal immunity: advances and implications.

Zhou M, Xiao H, Yang X, Cheng T, Yuan L, Xia N MedComm (2020). 2025; 6(2):e70056.

PMID: 39830020 PMC: 11739453. DOI: 10.1002/mco2.70056.


Induction of protective immune responses at respiratory mucosal sites.

Park S, Wiest M, Yan V, Wong P, Schotsaert M Hum Vaccin Immunother. 2024; 20(1):2368288.

PMID: 38953250 PMC: 11221474. DOI: 10.1080/21645515.2024.2368288.


Chitosan-Based Nanocarriers for Pulmonary and Intranasal Drug Delivery Systems: A Comprehensive Overview of their Applications.

Alwahsh W, Sahudin S, AlKhatib H, Bostanudin M, Alwahsh M Curr Drug Targets. 2024; 25(7):492-511.

PMID: 38676513 DOI: 10.2174/0113894501301747240417103321.


References
1.
Yanagita M, Hiroi T, Kitagaki N, Hamada S, Ito H, Shimauchi H . Nasopharyngeal-associated lymphoreticular tissue (NALT) immunity: fimbriae-specific Th1 and Th2 cell-regulated IgA responses for the inhibition of bacterial attachment to epithelial cells and subsequent inflammatory cytokine production. J Immunol. 1999; 162(6):3559-65. View

2.
Gebert A, Pabst R . M cells at locations outside the gut. Semin Immunol. 1999; 11(3):165-70. DOI: 10.1006/smim.1999.0172. View

3.
Hathaway L, Kraehenbuhl J . The role of M cells in mucosal immunity. Cell Mol Life Sci. 2000; 57(2):323-32. PMC: 11146756. DOI: 10.1007/PL00000693. View

4.
Partidos . Intranasal vaccines: forthcoming challenges. Pharm Sci Technol Today. 2000; 3(8):273-281. DOI: 10.1016/s1461-5347(00)00281-9. View

5.
Wang W . Lyophilization and development of solid protein pharmaceuticals. Int J Pharm. 2000; 203(1-2):1-60. DOI: 10.1016/s0378-5173(00)00423-3. View